Press Releases

16 Jun 2026 Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

Exclusivity Extended into December 2042 KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation

02 Jun 2026 Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is Well Capitalized with Nearly $30 Million Cash on Hand KANSAS CITY, Kan., June 02, 2026 (GLOBE

14 May 2026 Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Cash Position Grows to $25.9 Million KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported

18 Mar 2026 Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision

17 Feb 2026 Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by

Press Releases

16 Jun 2026 Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

02 Jun 2026 Cingulate Receives Complete Response Letter from FDA for CTx-1301

14 May 2026 Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

18 Mar 2026 Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

17 Feb 2026 Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Contact us